Overview

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

Status:
Completed
Trial end date:
2019-06-25
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
ACADIA Pharmaceuticals Inc.
Treatments:
Pimavanserin